Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancer types world-
wide. Its high mortality is related to the difficulty in the diagnosis, which often occurs when
the disease is already advanced. As of today, no early diagnostic tests are available, while
only a limited number of prognostic tests have reached clinical practice. The main reason is
the lack of reliable biomarkers that are able to capture the early development or the
progression of the disease. Hence, the discovery of biomarkers for early diagnosis or …